Compare Cadila Healthcare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 22.0 8.1 271.8% View Chart
P/BV x 2.6 1.0 253.8% View Chart
Dividend Yield % 1.3 1.0 135.0%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
GLENMARK PHARMA
Mar-19
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs432712 60.8%   
Low Rs306484 63.4%   
Sales per share (Unadj.) Rs128.6349.6 36.8%  
Earnings per share (Unadj.) Rs18.532.8 56.6%  
Cash flow per share (Unadj.) Rs24.444.3 55.0%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.90.3 283.1%  
Book value per share (Unadj.) Rs101.5198.6 51.1%  
Shares outstanding (eoy) m1,023.74282.17 362.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.7 168.1%   
Avg P/E ratio x19.918.2 109.3%  
P/CF ratio (eoy) x15.113.5 112.3%  
Price / Book Value ratio x3.63.0 121.0%  
Dividend payout %18.96.1 309.3%   
Avg Mkt Cap Rs m378,170168,625 224.3%   
No. of employees `00012.412.0 103.3%   
Total wages/salary Rs m21,24120,561 103.3%   
Avg. sales/employee Rs Th10,585.08,196.0 129.1%   
Avg. wages/employee Rs Th1,707.81,708.1 100.0%   
Avg. net profit/employee Rs Th1,526.5768.5 198.6%   
INCOME DATA
Net Sales Rs m131,65698,655 133.5%  
Other income Rs m2,0112,081 96.6%   
Total revenues Rs m133,667100,736 132.7%   
Gross profit Rs m29,73115,858 187.5%  
Depreciation Rs m5,9863,259 183.7%   
Interest Rs m1,9353,346 57.8%   
Profit before tax Rs m23,82111,335 210.2%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m5,3033,756 141.2%   
Profit after tax Rs m18,9879,250 205.3%  
Gross profit margin %22.616.1 140.5%  
Effective tax rate %22.333.1 67.2%   
Net profit margin %14.49.4 153.8%  
BALANCE SHEET DATA
Current assets Rs m84,98166,968 126.9%   
Current liabilities Rs m73,42540,211 182.6%   
Net working cap to sales %8.827.1 32.4%  
Current ratio x1.21.7 69.5%  
Inventory Days Days7583 89.4%  
Debtors Days Days11081 134.9%  
Net fixed assets Rs m133,49333,322 400.6%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m102,83955,770 184.4%   
Net worth Rs m103,86356,052 185.3%   
Long term debt Rs m39,49735,738 110.5%   
Total assets Rs m234,831132,888 176.7%  
Interest coverage x13.34.4 303.4%   
Debt to equity ratio x0.40.6 59.6%  
Sales to assets ratio x0.60.7 75.5%   
Return on assets %8.99.5 94.0%  
Return on equity %18.316.5 110.8%  
Return on capital %18.317.8 102.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40462,998 76.8%   
Fx outflow Rs m11,59322,859 50.7%   
Net fx Rs m36,81140,140 91.7%   
CASH FLOW
From Operations Rs m28,82313,242 217.7%  
From Investments Rs m-57,387-6,990 821.0%  
From Financial Activity Rs m18,846-7,387 -255.1%  
Net Cashflow Rs m-7,105-2,971 239.2%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,028 Points; Oil & Gas, FMCG and Metal Stocks Rally(Closing)

Indian share markets continued to trade in the green during closing hours and ended their day on a strong note, tracking global cues.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 31, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - FULFORD INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS